Press Releases

‘UK government can deliver Brexit benefit with world’s best medicines security’ say FarmaTrust

Company forewarns the UK is risking fake COVID-19 vaccines and other medicines without a new system

RheinCell Therapeutics Achieves Milestone GMP Certification to Manufacture Cord Blood-Derived iPSCs for Safe and Compliant Cell Therapies

RheinCell Therapeutics GmbH, a developer and manufacturer of human induced pluripotent stem cells (iPSCs) as starting materials for cell therapies, has announced it has received Good Manufacturing Practice (GMP) certification and Manufacturing Authorization. The GMP certification paves the way for the company to deliver fully characterized clinical-grade iPSCs that are derived from human cord blood cells for the development of cell-based therapies. This marks a landmark achievement for RheinCell, which is now among a select few iPSCs manufacturers to have received the critical certification.

Gut Microbiota Bioinformatics Services Now Available by the GutFlora Omics Platform

GutFlora Omics platform belongs to Creative Proteomics. It has more than 10 years of experience in providing advanced multi-omics services, and provides services and support to customers through comprehensive intestinal flora research solutions. The product manager has recently announced the fully-developed gut microbiota bioinformatics services, which help understand how the gut microbiota colonizes, varies and interacts with the host, and even how to associate with diseases can be of great value in the treatment of these diseases, such as inflammatory bowel disease (IBD), diabetes, mental disorders, and cancers.

Ubiquigent and the University of York Awarded a Grant to Explore the Potential of Deubiquitylase (DUB) Enzyme Inhibitors to Address Neglected Tropical Diseases

Ubiquigent today announced a collaboration with Mottram Laboratory at the University of York to investigate the inhibition of deubiquitylase (DUB) enzymes expressed by the protozoan Leishmania mexicana for the treatment of leishmaniasis.

Global healthtech company Raremark appoints Nicki Grundy as its Chief Financial Officer

Raremark, the global healthtech company specialising in rare disease, has appointed Nicki Grundy as Chief Financial Officer to support the accelerated levels of growth the company is experiencing.

MedAI: Explore Therapeutic Antibody Discovery and Development for Disease Treatment

Bio-drugs are more extensively used in disease treatment, especially in the past decade. MedAI, an expert of AI-assisted R&D research company, announces that it now provides AI-driven solutions for the development of therapeutic antibodies, which could be used for the treatment of pathologies such as oncology.

Pronalyse Division Announced Vaccines Analysis Service to Ensure Vaccine Safety

Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development service for over 10 years. Pronalyse is dedicated to providing professional analysis services in biopharmaceutical development. Recently, the product manager has announced the vaccines analysis service to ensure the safety, efficacy, purity and potency of vaccine products.

Alfa Chemistry: Instrumental Analytical Reagents Are Now Accessible

Alfa Chemistry announced in a statement that the company starts to provide varieties of instrumental analytical reagents for consumers worldwide. In addition to other reagents that are previously released, now the company’s supply range of products are widely broadened, which encompasses: chromatography standards and derivatization reagents, Ion Sensor Materials, Laboratory Supplies, LPLC/TLC/Paper Chromatography, and Titration.

BOC Sciences’s CDMO Helps Overcome the Last Hurdle of ADC R&D

Panthera began dosing volunteers in AstraZeneca’s phase III of its long-acting antibody combination AZD7442 for the prevention of COVID-19 at its sites in Preston, North Manchester and North London

Panthera’s clinical trial sites are helping to evaluate an alternative AstraZeneca vaccine for people who are unable to have the currently approved Covid-19 vaccines. The treatment is aimed at helping those people with a compromised immune system, who cannot be vaccinated, vaccine hesitant and those who are unlikely to respond to a vaccination.

IntegrateRNA Provided Innovative mRNA Solutions for Research of Life Sciences, Clinical and Drug Development

Enveda Biosciences Systematically Harnesses Untapped Potential of Nature’s Chemistry to Develop Next-Gen Therapeutics

BOC Sciences Upgrades Impurity Isolation and Identification Service to Help Advance Drug Research

Profacgen Provides Comprehensive Solutions for PEGylation

 Protheragen Offers Acquisition Opportunity for A Complete Pentapeptide Library

Data Analysis at AI & Medicine: PrediXcan Based Analysis and BSLMM Prediction

AMZELL to initiate FDA-approved Phase 3 trial of innovative injectable treatment for infantile epileptic disease

AMZELL B.V to initiate a Phase 3 trial of its new treatment for infantile epileptic disease, AMZ002.

BioIVT Announces Charitable Donations to Honor its Clients’ Commitment to Medical Research

BioIVT is contributing to four healthcare organizations this year, focusing on cancer, liver diseases, Alzheimer’s disease, and global health equity.

Cytel Acquires HEOR Experts Purple Squirrel Economics

Cytel has today announced the acquisition of Purple Squirrel Economics, expanding Cytel’s distinguished real world and advanced analytics team and further growing the global reach of Cytel’s extensive Health Economics Outcomes Research (HEOR) expertise. The acquisition marks the latest step in Cytel’s commitment to continue powering pharmaceutical development through novel applications of modern data analytics, and follows the company’s recent acquisitions of both MTEK Sciences and Ingress Health in the past year. Based in the US and Canada, Purple Squirrel Economics offers strategic leadership with a global perspective by engaging a team of senior health economists, HEOR value communication writers, research analysts, and market access professionals trusted by both regulators and payers. They help companies prove product value with rigorous quantitative insights, thereby driving products towards commercial success.

CCT Research Expands Clinical Trial Capabilities to Salt Lake City

CCT Research involved in COVID-19 vaccine research expands to Utah, partnering with local physician practices to enhance trial participation.